中华物理医学与康复杂志
中華物理醫學與康複雜誌
중화물리의학여강복잡지
CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION
2012年
2期
120-124
,共5页
刘建军%纪树荣%胡莹媛%李燕春%吴卫红%陆华宝%张雁
劉建軍%紀樹榮%鬍瑩媛%李燕春%吳衛紅%陸華寶%張雁
류건군%기수영%호형원%리연춘%오위홍%륙화보%장안
脑性瘫痪%痉挛%神经阻滞术%A型肉毒毒素%酚阻滞术
腦性癱瘓%痙攣%神經阻滯術%A型肉毒毒素%酚阻滯術
뇌성탄탄%경련%신경조체술%A형육독독소%분조체술
Cerebral palsy%Spasticity%Nerve blocking%Botulinum toxin-A%Phenol blocking
目的 比较A型肉毒毒素(BTX-A)阻滞术和酚阻滞术缓解脑性瘫痪患儿痉挛的优劣.方法 420例痉挛型脑瘫患儿(男271例,女149例),年龄1~22岁,平均6.87岁.依据患儿的就诊时间分为对照组和实验组,均行痉挛的小腿三头肌(腓肠肌、比目鱼肌)神经阻滞术.1997年7月至2000年1月收治的患儿设为对照组,共45例,应用5%的酚溶液行神经阻滞术治疗,用量为0.5 ~4.6 ml,平均2.2 ml;2000年1月至2010年2月收治的患儿设为实验组,375例,应用BTX-A行神经阻滞术治疗,用量为55~350 IU,平均130.5 IU.在阻滞术后,2组患儿均进行系统的功能康复训练.于神经阻滞术前、后分别采用医师评定量表( PRS)评分进行运动功能评价,采用修改的Ashworth评分法对2组脑瘫患儿的痉挛程度进行评定.并对这2种药物行神经阻滞术的疗效、疗效持续时间及药物的不良反应发生情况进行对比观察.结果 术前2组脑瘫患儿的运动障碍功能程度及痉挛程度组间差异无统计学意义(P>0.05),具有可比性.术后2组患儿的痉挛程度均下降,组内差异有统计学意义(P<0.01).实验组BTX-A阻滞术的有效率为98.4%,对照组酚阻滞术的有效率为95.6%,2组患儿的疗效差异无统计学意义(P>0.05);实验组的疗效持续时间为(24.9±5.76)周,对照组的疗效持续时间平均为(69.2±13.76)周,明显长于实验组患儿(P<0.01);实验组的不良反应发生率为5.33%,对照组患儿的不良反应发生率为15.56%,明显高于实验组患儿(P<0.01).结论 BTX-A神经阻滞术更安全、更可靠,具有更广阔的发展前景.
目的 比較A型肉毒毒素(BTX-A)阻滯術和酚阻滯術緩解腦性癱瘓患兒痙攣的優劣.方法 420例痙攣型腦癱患兒(男271例,女149例),年齡1~22歲,平均6.87歲.依據患兒的就診時間分為對照組和實驗組,均行痙攣的小腿三頭肌(腓腸肌、比目魚肌)神經阻滯術.1997年7月至2000年1月收治的患兒設為對照組,共45例,應用5%的酚溶液行神經阻滯術治療,用量為0.5 ~4.6 ml,平均2.2 ml;2000年1月至2010年2月收治的患兒設為實驗組,375例,應用BTX-A行神經阻滯術治療,用量為55~350 IU,平均130.5 IU.在阻滯術後,2組患兒均進行繫統的功能康複訓練.于神經阻滯術前、後分彆採用醫師評定量錶( PRS)評分進行運動功能評價,採用脩改的Ashworth評分法對2組腦癱患兒的痙攣程度進行評定.併對這2種藥物行神經阻滯術的療效、療效持續時間及藥物的不良反應髮生情況進行對比觀察.結果 術前2組腦癱患兒的運動障礙功能程度及痙攣程度組間差異無統計學意義(P>0.05),具有可比性.術後2組患兒的痙攣程度均下降,組內差異有統計學意義(P<0.01).實驗組BTX-A阻滯術的有效率為98.4%,對照組酚阻滯術的有效率為95.6%,2組患兒的療效差異無統計學意義(P>0.05);實驗組的療效持續時間為(24.9±5.76)週,對照組的療效持續時間平均為(69.2±13.76)週,明顯長于實驗組患兒(P<0.01);實驗組的不良反應髮生率為5.33%,對照組患兒的不良反應髮生率為15.56%,明顯高于實驗組患兒(P<0.01).結論 BTX-A神經阻滯術更安全、更可靠,具有更廣闊的髮展前景.
목적 비교A형육독독소(BTX-A)조체술화분조체술완해뇌성탄탄환인경련적우렬.방법 420례경련형뇌탄환인(남271례,녀149례),년령1~22세,평균6.87세.의거환인적취진시간분위대조조화실험조,균행경련적소퇴삼두기(비장기、비목어기)신경조체술.1997년7월지2000년1월수치적환인설위대조조,공45례,응용5%적분용액행신경조체술치료,용량위0.5 ~4.6 ml,평균2.2 ml;2000년1월지2010년2월수치적환인설위실험조,375례,응용BTX-A행신경조체술치료,용량위55~350 IU,평균130.5 IU.재조체술후,2조환인균진행계통적공능강복훈련.우신경조체술전、후분별채용의사평정량표( PRS)평분진행운동공능평개,채용수개적Ashworth평분법대2조뇌탄환인적경련정도진행평정.병대저2충약물행신경조체술적료효、료효지속시간급약물적불량반응발생정황진행대비관찰.결과 술전2조뇌탄환인적운동장애공능정도급경련정도조간차이무통계학의의(P>0.05),구유가비성.술후2조환인적경련정도균하강,조내차이유통계학의의(P<0.01).실험조BTX-A조체술적유효솔위98.4%,대조조분조체술적유효솔위95.6%,2조환인적료효차이무통계학의의(P>0.05);실험조적료효지속시간위(24.9±5.76)주,대조조적료효지속시간평균위(69.2±13.76)주,명현장우실험조환인(P<0.01);실험조적불량반응발생솔위5.33%,대조조환인적불량반응발생솔위15.56%,명현고우실험조환인(P<0.01).결론 BTX-A신경조체술경안전、경가고,구유경엄활적발전전경.
Objective To compare the advantages and disadvantages of botulinum toxin A (BTX-A) and phenol block in the treatment of spasticity in children with cerebral palsy. Methods Four hundred and twenty children with spastic cerebral palsy were divided into an experimental group (375 cases) and a control group (45 cases).The children were aged from 1 to 22 years ( average age 6 years).The children in the experimental group were treated with BTX-A block at a dosage of 55 to 350 IU (average 130.5 IU).The children in the control group were treated with a 5% phenol solution block at a dosage of 0.5 to 4.6 ml ( average 2.2 ml).Children of both groups were given systematic functional rehabilitation training. All the children were evaluated with a physician rating scale (PRS) and the modified Ashworth scale (MAS) before and after the blocking.Effectiveness rates,effectiveness durations and side effects rates were calculated. Results Before treatment there was no significant difference in terms of motor disorder or spasticity between the 2 groups.After treatment,spasticity had been significantly reduced in both groups.The effectiveness rate was 98.4% in the experimental group and 95.6% in the control group,a difference which was not significant.The average effectiveness duration was ( 24.9 ± 5.76 ) weeks in the experimental group and ( 69.2 ± 13.76) weeks in the control group,significantly longer.The side effects rate was 5.33 % in the experimental group and 15.56% in the control group,also a significant difference. Conclusion BTX-A could be more widely used because of its safety and credibility.